October 1, 2020 Ran Frankel Dear Ran:Karyopharm Therapeutics Inc. • May 5th, 2022 • Pharmaceutical preparations
You and Karyopharm Therapeutics Inc. (the “Company”) are parties to a letter agreement dated June 7, 2015, as amended on October 4, 2016, related to your employment as the Chief Development Operations Officer of the Company (the “Letter Agreement”). This letter is to inform you that, effective August 28, 2020 the Compensation Committee of the Board of Directors of the Company approved certain enhanced severance benefits for you, as described below, in addition to the benefits you may be entitled to under the Letter Agreement. Except as specifically set forth below, the Letter Agreement remains in full force and effect, and no provisions thereof are amended except as set forth below. Capitalized terms used but not defined herein shall have the meaning set forth in the Letter Agreement.
VIA E-MAIL February 18, 2022 Jatin Shah, M.D. Bellaire, Texas 77401 Dear Jatin:Karyopharm Therapeutics Inc. • May 5th, 2022 • Pharmaceutical preparations • Massachusetts
As we discussed, your employment with Karyopharm Therapeutics Inc. (the “Company”) will end effective at the close of business on February 18, 2022 (the “Separation Date”). As we also discussed, you will be eligible to receive the severance benefits described in paragraph 1 below if you sign and return this letter agreement to me by March 14, 2022 (but no earlier than February 18, 2022) and do not revoke your agreement (as described below). By signing and returning this letter agreement and not revoking your acceptance, you will be entering into a binding agreement with the Company and will be agreeing to the terms and conditions set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 2. Therefore, you are advised to consult with an attorney before signing this letter agreement and you have been given at least twenty-one (21) days to do so. If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (
AMENDMENT #1 TO CONSULTING AGREEMENT BETWEEN KARYOPHARM THERAPEUTICS INC. AND JATIN SHAH, M.D.Consulting Agreement • May 5th, 2022 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations
THIS AMENDMENT #1 (“Amendment”) amends the Consulting Agreement between Karyopharm Therapeutics Inc. (“Karyopharm”) and Jatin Shah, M.D. (“Consultant”) with an Effective Date of the 1st day of March 2022, (the “Agreement”). This Amendment shall be effective as of March 21, 2022 (the “Amendment 1 Effective Date”).
CONSULTING AGREEMENTConsulting Agreement • May 5th, 2022 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (the “Agreement”), effective as of the Effective Date (as defined herein), is entered into between Karyopharm Therapeutics Inc. (the “Company”) and Jatin Shah, M.D. (the “Consultant”). The Consultant and the Company are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
